drugset / Trial / NCT01299038
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Phase 2
Completed
20 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collabMassachusetts General Hospital · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelSupportive care
Summary
Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. Studies have demonstrated that increases in microparticles may contribute to the development of deep vein thrombosis in cancer patients. The purpose of this research study is to see if rosuvastatin lowers the number of tissue factor bearing microparticles in the blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-11
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rosuvastatin | Small molecule | 20 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 40 mg | Oral |